Jon Napitupulu

Windward Bio has launched its Phase 2 POLARIS clinical trial to assess the long-acting dosing of WIN378, an anti-TSLP...

PROCEPT BioRobotics announced the successful completion of three prostate cancer procedures using Aquablation therapy in an ambulatory surgery center...

In a 242-patient Phase 2b trial for cognitive impairment associated with schizophrenia (CIAS), inidascamine (formerly RL-007) failed to meet...

BriaCell Therapeutics Corp. will present two clinical data posters at the European Society for Medical Oncology (ESMO) Congress 2025...

Liminatus Pharma, a preclinical-stage biopharmaceutical company focused on cancer immunotherapy development, has partnered with Digital Offering LLC to explore...

CervoMed (NASDAQ: CRVO) will share 32-week primary endpoint results from the extension phase of its Phase 2b RewinD-LB study...

NextCure, Inc. announced preclinical data for NC605, an anti-Siglec-15 antibody, showing improved bone microarchitecture and reduced fractures in an...

Celcuity Inc. has initiated VIKTORIA-2, a Phase 3 clinical trial investigating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant...

Revolution Medicines announced the publication of research in •Science• detailing the discovery and development of zoldonrasib, a covalent inhibitor...

Unicycive Therapeutics announced positive results from a Phase 2 trial of its investigational phosphate binder, oxylanthanum carbonate (OLC), for...